Leerink Partners analyst Andrew Berens maintained a Buy rating on AstraZeneca (AZN – Research Report) yesterday. The company's shares closed last Friday at $66.40. According to TipRanks.com, Berens is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.9% and a 37.7% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals. AstraZeneca has an analyst consensus of Moderate Buy. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $71.70 and a one-year low of $50.66. Currently, AstraZeneca has an average volume of 8.03M.
https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-buy-from-leerink-partners?utm_source=advfn.com&utm_medium=referral
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2022 bis Jun 2022 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jun 2021 bis Jun 2022 Click Here for more AstraZeneca Charts.